Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2005

View Archived Issues

Dopamine transporter ligand identified with potential efficacy as a treatment for cocaine addiction

Mechanism of action of the antiinflammatory effects of erythromycin in vivo

NCX-4016 reported to decrease platelet activation in patients with type 2 diabetes

Good safety profile found for Adenovirus Type-5 HIV vaccines in healthy subjects

Cytolin decreases viral load and increases T-cell count in HIV-infected patients

Pharmacopeia and Celgene select compound for development

3M and Takeda sign agreement for HPV infection and cervical dysplasia

Helix subsidiary signs agreement with Apotex

A novel PAR2 agonist induces gastric mucosal cytoprotection

Second phase I study for MPC-6827

OSI-930 enters clinical development

Mechanisms of CB2 cannabinoid receptor antinociception

Phase II study for antianxiety agent MN-305

Mechanism of action of the HIV-1 attachment inhibitor, BMS-488043

Full enrollment reached in phase II MATCHED study of MC-4232

SP-01A set to enter phase II/III study in Q2

GenPath becomes AVEO Pharmaceuticals

OccuLogix cleared to begin crossover studies of RHEO system for dry AMD

Preclinical activity of a novel nonpeptide selective vasopressin V1A receptor antagonist, YM-218

Non-approvable letter for Lexapro in panic disorder

Exubera NDA accepted for filing

Norpiperidine imidazoazepines: a novel class of selective nonsedative H1 antihistamines

New opioid receptor antagonists for gastrointestinal dysfunction disclosed by Adolor

AstraZeneca claims novel Aurora kinase inhibitors for the treatment of cancer

New cannabinoid CB1 receptor modulators prepared and tested at AstraZeneca

New treatment for varicose veins described in patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...